Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …

Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study
(IMPRESS) compared the continuation of gefitinib plus chemotherapy with placebo plus …

Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …

Background Optimum management strategies for patients with advanced non-small-cell
lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are …

7504 Background: Somatic EGFR mutations correlate with increased response and survival
in NSCLC patients (pts) treated with gefitinib. We conducted the 1st prospective US trial of …

PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …

Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (ie, EGFR-
TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the …

Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Objective: There is no standard care for advanced non–small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …